| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Eyetech Research Center, Lexington, Massachusetts
‘Vascular endothelial growth factor-A (VEGF-A) blockade has been recently validated as an effective strategy for the inhibition of new blood vessel growth in cancer and ocular pathologies. However, several studies have also shown that anti-VEGF therapy may not be as effective in the treatment of established unwanted blood vessels, suggesting they may become less dependent on VEGF-A for survival. The VEGF-A dependence of vessels may be related to the presence of vascular mural cells (pericytes or smooth muscle cells). Mural cell recruitment to the growing endothelial tube is regulated by platelet-derived growth factor-B (PDGF-B) signaling, and interference with this pathway causes disruption of endothelial cell-mural cell interactions and loss of mural cells. We have investigated the basis of blood vessel dependence on VEGF-A in models of corneal and choroidal neovascularization using a combination of reagents (an anti-VEGF aptamer and an anti-PDGFR-ß antibody) to inhibit both the VEGF-A and PDGF-B signaling pathways. We demonstrate that neovessels become refractory to VEGF-A deprivation over time. We also show that inhibition of both VEGF-A and PDGF-B signaling is more effective than blocking VEGF-A alone at causing vessel regression in multiple models of neovascular growth. These findings provide insight into blood vessel growth factor dependency and validate a combination therapy strategy for enhancing the current treatments for ocular angiogenic disease.
This article has been cited by other articles:
 |
|
 |
|
  P. K Kaiser Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand? Br J Ophthalmol, February 1, 2010; 94(2): 143 - 145. [Full Text] [PDF]
|
|
|
|
|
|
C. Costagliola, M. R Romano, M. Rinaldi, R. dell'Omo, F. Chiosi, M. Menzione, and F. Semeraro Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration Br J Ophthalmol, February 1, 2010; 94(2): 180 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hollborn, C. Petto, A. Steffen, S. Trettner, A. Bendig, P. Wiedemann, A. Bringmann, and L. Kohen Effects of Thrombin on RPE Cells Are Mediated by Transactivation of Growth Factor Receptors Invest. Ophthalmol. Vis. Sci., September 1, 2009; 50(9): 4452 - 4459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E J Chung, S Yoo, H J Lim, S H Byeon, J H Lee, and H J Koh Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib Br J Ophthalmol, July 1, 2009; 93(7): 958 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takahashi, Y. Saishin, Y. Saishin, A. G. King, R. Levin, and P. A. Campochiaro Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib Arch Ophthalmol, April 1, 2009; 127(4): 494 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Edelhauser, J. H. Boatright, J. M. Nickerson, and the Third ARVO/Pfizer Research Institute Working G Drug Delivery to Posterior Intraocular Tissues: Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4712 - 4720. [Full Text] [PDF]
|
|
|
|
|
|
A C Browning, H S Dua, and W M Amoaku The effects of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells Br J Ophthalmol, July 1, 2008; 92(7): 1003 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Andrae, R. Gallini, and C. Betsholtz Role of platelet-derived growth factors in physiology and medicine Genes & Dev., May 15, 2008; 22(10): 1276 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ju, C. Mailhos, J. Bradley, T. Dowie, M. Ganley, G. Cook, P. Calias, N. Lange, A. P. Adamis, D. T. Shima, et al. Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ameri, G. J. Chader, J.-G. Kim, S. R. Sadda, N. A. Rao, and M. S. Humayun The Effects of Intravitreous Bevacizumab on Retinal Neovascular Membrane and Normal Capillaries in Rabbits Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5708 - 5715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Groenman, M. Rutter, J. Wang, I. Caniggia, D. Tibboel, and M. Post Effect of chemical stabilizers of hypoxia-inducible factors on early lung development Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L557 - L567. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
